Tag Archives: Johnson & Johnson

At SEMICON Europa – November 2019 – strong focus on medical technologies (MedTech)

Semicom Europa MedTechThis year SEMICON Europa (12-15th November 2019, Munich) will have a strong focus on state-of-the-art medical technologies (MedTech), offering the SMART MedTech Forum as Europe’s first event to foster collaboration in semiconductor value chains and medical technologies.

Janssen Pharmaceutical Companies from Johnson & Johnson will kick off the forum with a presentation on the challenges and opportunities in the healthcare world, followed by MedTech Europe, which will discuss trends in the areas of healthcare and digital medical technologies. IMEC and GE Research will focus on bridging the gap between semiconductors and medical technologies to address global health challenges.

Digital medicine promises to prevent and cure diseases and transform health care through personalized treatment. EPFL experts Lausanne, Philips, Robert Bosch GmbH, and Bart’s Heart Center will discuss considerable advances in personalized treatment, including the use of artificial organs, organs-on-a-chips and human avatars as the next paradigm in health care.

Click here for more…

Digital Health

Digital HealthDigital Health is becoming the new frontier of the Digital Transformation due to its impact on social basis. To understand the importance of this field or research and business, consider big part of the investment put in place by pharma and healthcare companies all over the world: Johnson & Johnson built the technological incubator, GE Healthcare set up a brand new branch called Digital and more and more example could follow. Just to give you an idea of the impact, the FDA published a page (Mobile Health Apps Interactive Tool) to give precise advice on how to develop new technologies following the necessary regulatory aspect.

All these new applications would not been able to have this kind of technological increasing without the necessary basis: Cloud Computing, Big Data, Wearable Computing are the most important, without these “new tech” any possible development could be sometimes so expensive and some other probably technically impossible.

Last but not least the epidemiological studies which could be put in place via the big data analysis should have an incredible impact in terms of public safety control, to enhance efficiency in the healthcare, avoiding costs and losing time for the patients / operators, having as final results to save economical resource within the public health sector which is under enormous pressure since years.

What are the main areas of application?
• Wireless Medical Devices
• Mobile medical apps
• Health IT
• Telemedicine
• Medical Device Data Systems
• Medical device Interoperability
• Software as a Medical Device (SaMD)
• General Wellness
• Cybersecurity

JLABS the start up incubator

JlabsThe healthcare and pharma arena has a proper necessity of innovation. Most of the big companies spend every year more the 10% of the their income in R&D or adopt a different approach, the acquisition of innovative little companies or start-up.

Johnson & Johnson tries the third way: invest into a start-up incubator to accelerate the innovative solutions from design to ‘go to market’, this is JLABS.
I personally think that this is a winning point: J&J has not only the necessary funds to invest and to put together the necessary facilities to facilitate the scientists/start-uppers, but J&J as all the pharma/healthcare companies knows very well the regulatory and registration mechanisms in this complex market and that’s why they put together an ecosystem to help te new-co on these tasks.

Below you can find some of the most interesting research companies included by the JLABS program: consider also the cross-pollination process which could be a natural consequence of having all people working in the same place who could have same problem / solutions to share.

Analytical 4 Life
JLABS @ Toronto
Analytics 4 Life (A4L) has developed a proprietary signal processing and machine intelligence platform, Agilytics™, to produce machine-learned solutions for the purposes of detecting disease. Agilytics™ works by mathematically deciphering critical patterns and relationships from billions of captured data points paired with clinical results.

JLABS @ Toronto
Mediphage Bioceuticals (MB) is a School of Pharmacy, University of Waterloo research group and spin-off biotechnology firm that focuses on the manipulation of bacteriophages to develop new therapeutics and cosmeceuticals.

JLABS @ Toronto
Vasomune Therapeutics is a Toronto-based biotechnology company developing first in class therapies to target a range of acute vascular complications.

JLABS @ Toronto
Densitas Inc. is an ISO 13485-certified medical technology company that develops data-driven solutions for clinical decision making.

JLABS @ Toronto
About us
DoseBiome is focused on innovative oral microbiome research that improves the microbial ecosystem in the mouth by preventing diseases such as dental caries and periodontal conditions.